Insights from in vivo modification of adrenergic receptor gene expression

Annual Review of Pharmacology and Toxicology

Volumn 38, Issue , 1998, Pages 351-373

  Rohrer, Daniel K ^a   Kobilka, Brian K ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Knockout; Pharmacology; Physiology; Subtype; Transgenic

Indexed keywords

ADRENERGIC RECEPTOR;

ADRENERGIC SYSTEM; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS;

EUKARYOTA;

EID: 0031779719     PISSN: 00664251     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.38.1.351     Document Type: Review

References (102)

1. Strader CD, Fong TM, Graziano MP, Tota MR. 1995. The family of G-protein-coupled receptors. FASEB J. 9(9):745-54
2. Hoffman BB, Lefkowitz RJ. 1996. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In The Pharmacological Basis of Therapeutics, ed. JG Hardman, LE Limbird, PM Molinoff, RW Ruddon. pp. 199-248. New York: McGraw-Hill
3. Schwinn DA, Page SO, Middleton JP, Lorenz W, Liggett SB, et al. 1991. The alpha 1C-adrenergic receptor: characterization of signal transduction pathways and mammalian tissue heterogeneity. Mol. Pharmacol. 40(5):619-26
4. Wu D, Katz A, Lee CH, Simon MI. 1992. Activation of phospholipase C by alpha 1-adrenergic receptors is mediated by the alpha subunits of Gq family. J. Biol. Chem. 267(36):25798-802
5. Bylund DB, Regan JW, Faber JE, Hieble JP, Triggle CR, et al. 1995. Vascular alpha-adrenoceptors: from the gene to the human. Can. J. Physiol. Pharmacol. 73(5):533-43
6. Cotecchia S, Schwinn DA, Randall RR, Lefkowitz RJ, Caron MG, et al. 1988. Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. Proc. Natl. Acad. Sci. USA 85(19):7159-63
7. Schwinn DA, Lomasney JW, Lorenz W, Szklut PJ, Fremeau RJ, et al. 1990. Molecular cloning and expression of the cDNA for a novel alpha 1-adrenergic receptor subtype. J. Biol. Chem. 265(14):8183-89
8. Lomasney JW, Cotecchia S, Lorenz W, Leung WY, Schwinn DA, et al. 1991. Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. J. Biol. Chem. 266(10):6365-69
9. Perez DM, Piascik MT, Graham RM. 1991. Solution-phase library screening for the identification of rare clones: isolation of an alpha 1D-adrenergic receptor cDNA. Mol. Pharmacol. 40(6):876-83
10. Muramatsu I, Ohmura T, Kigoshi S, Hashimoto S, Oshita M. 1990. Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle. Br. J. Pharmacol. 99(1):197-201
11. Kurose H, Regan JW, Caron MG, Lefkowitz RJ. 1991. Functional interactions of recombinant alpha 2 adrenergic receptor subtypes and G proteins in reconstituted phospholipid vesicles. Biochemistry 30(13):3335-41
12. Coupry I, Duzic E, Lanier SM. 1992. Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. II. Preferential coupling of the alpha 2C-adrenergic receptor to the guanine nucleotide-binding protein, Go. J. Biol. Chem. 267(14):9852-57
13. Duzic E, Coupry I, Downing S, Lanier SM. 1992. Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. I. Coupling of alpha 2-adrenergic receptor subtypes to distinct G-proteins. J. Biol. Chem. 267(14):9844-51
14. Eason MG, Kurose H, Holt BD, Raymond JR, Liggett SB. 1992. Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs. J. Biol. Chem. 267(22):15795-801
15. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. 1996. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273(5276):801-3
16. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, et al. 1996. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 273(5276):803-5
17. MacKinnon AC, Spedding M, Brown CM. 1994. Alpha 2-adrenoceptors: more subtypes but fewer functional differences. Trends. Pharmacol. Sci. 15(4):119-23
18. Link R, Daunt D, Barsh G, Chruscinski A, Kobilka B. 1992. Cloning of two mouse genes encoding alpha 2-adrenergic receptor subtypes and identification of a single amino acid in the mouse alpha 2-C10 homolog responsible for an interspecies variation in antagonist binding. Mol. Pharmacol. 42(1):16-27
19. Dixon RA, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, et al. 1986. Cloning of the gene and cDNA for mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 321(6065):75-79
20. Frielle T, Collins S, Daniel KW, Caron MG, Lefkowitz RJ, et al. 1987. Cloning of the cDNA for the human beta 1-adrenergic receptor. Proc. Natl. Acad. Sci. USA 84(22):7920-24
21. Emorine LJ, Marullo S, Briend SM, Patey G, Tate K, et al. 1989. Molecular characterization of the human beta 3-adrenergic receptor. Science 245(4922):1118-21
22. Xiao RP, Ji X, Lakatta EG 1995. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol. Pharmacol. 47(2):322-29
23. Gauthier C, Tavernier G, Charpentier F, Langin D, Le MH. 1996. Functional beta3-adrenoceptor in the human heart [see comments]. J. Clin. Invest. 98(2): 556-62
24. Lands AM, Luduena FP, Buzzo HJ. 1967. Differentiation of receptors responsive to isoproterenol. Life Sci. 6(21):2241-49
25. Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TJ. 1967, Differentiation of receptor systems activated by sympathomimetic amines. Nature 214(88):597-98
26. Harms HH, Zaagsma J, de Vente J. 1977. Differentiation of beta-adrenoceptors in right atrium, diaphragm and adipose tissue of the rat, using stereoisomers of propranolol, alprenolol, nifenalol and practolol. Life Sci. 21(1):123-28
27. Arch JR, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, et al. 1984. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature 309(5964):163-65
28. Strosberg AD. 1997. Structure and function of the beta 3-adrenergic receptor. Annu. Rev. Pharmacol. Toxicol. 37(421): 421-50
29. Lafontan M, Berlan M. 1993. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res. 34(7):1057-91
30. Gross G, Hanft G, Mehdorn HM. 1989. Demonstration of alpha 1A- and alpha 1B-adrenoceptor binding sites in human brain tissue. Eur. J. Pharmacol. 169(2-3): 325-28
31. Hanft G, Gross G. 1989. Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br. J. Pharmacol. 97(3):691-700
32. 2+ channels and to a subtype of alpha 1-adrenoceptors. Eur. J. Pharmacol. 172(2):131-45
33. Van Waarde A, Meeder JG, Blanksma PK, Brodde OE, Visser GM, et al. 1992. Uptake of radioligands by rat heart and lung in vivo. CGP 12177 does and CGP 26505 does not reflect binding to beta-adrenoceptors. Eur. J. Pharmacol. 222(1):107-12
34. Wei LN. 1997. Transgenic animals as new approaches in pharmacological studies. Annu. Rev. Pharmacol. Toxicol. 37(119): 119-41
35. Jaenisch R, Mintz B. 1974. Simian virus 40 DNA sequences in DNA of healthy adult mice derived from preimplantation blastocysts injected with viral DNA. Proc. Natl. Acad. Sci. USA 71(4):1250-54
36. Jaenisch R, Fan H, Croker B. 1975. Infection of preimplantation mouse embryos and of newborn mice with leukemia virus: tissue distribution of viral DNA and RNA and leukemogenesis in the adult animal. Proc. Natl. Acad. Sci. USA 72(10):4008-12
37. Jaenisch R. 1976. Germ line integration and Mendelian transmission of the exogenous Moloney leukemia virus. Proc. Natl. Acad. Sci. USA 73(4):1260-64
38. Mullins LJ, Mullins JJ. 1996. Transgenesis in the rat and larger mammals. J. Clin. Invest. 97(7):1557-60
39. Gulick J, Subramaniam A, Neumann J, Robbins J. 1991. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J. Biol. Chem. 266(14): 9180-85
40. Furth PA, Stonge L, Boger H, Gruss P, Gossen M, et al. 1994. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc. Natl. Acad. Sci. USA 91(20):9302-6
41. Kistner A, Gossen M, Zimmermann F, Jerecic J, Ullmer C, et al. 1996. Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. Proc. Natl. Acad. Sci. USA 93(20):10933-38
42. No D, Yao TP, Evans RM. 1996. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. USA 93(8):3346-51
43. Capecchi MR. 1994. Targeted gene replacement. Sci. Am. 270(3):52-59
44. Wood SA, Allen ND, Rossant J, Auerbach A, Nagy A. 1993. Non-injection methods for the production of embryonic stem cell-embryo chimaeras. Nature 365(6441):87-89
45. Hasty P, Ramirez SR, Krumlauf R, Bradley A. 1991. Introduction of a subtle mutation into the Hox-2.6 locus in embryonic stem cells. Nature 350(6315):243-46; Erratum 353(6339):94
46. Hanks M, Wurst W, Anson CL, Auerbach AB, Joyner AL. 1995. Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2 [see comments]. Science 269(5224):679-82
47. Wang Y, Schnegelsberg PN, Dausman J, Jaenisch R. 1996. Functional redundancy of the muscle-specific transcription factors Myf5 and myogenin. Nature 379(6568):823-25
48. Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K. 1994. Deletion of a DNA polymerase beta gene segment in T cells using cell type-specific gene targeting [see comments]. Science 265(5168):103-6
49. Kuhn R, Schwenk F, Aguet M, Rajewsky K. 1995. Inducible gene targeting in mice. Science 269(5229):1427-29
50. Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, et al. 1996. Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res. 24(4):543-48
51. Copp AJ. 1995. Death before birth: clues from gene knockouts and mutations [see comments]. Trends Genet. 11(3):87-93
52. Simpson P. 1983. Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response. J. Clin. Invest. 72(2):732-38
53. Starksen NF, Simpson PC, Bishopric N, Coughlin SR, Lee WM, et al. 1986. Cardiac myocyte hypertrophy is associated with c-myc protooncogene expression. Proc. Natl. Acad. Sci. USA 83(21):8348-50
54. Simpson P, Bishopric N, Coughlin S, Karliner J, Ordahl C, et al. 1986. Dual trophic effects of the alpha 1-adrenergic receptor in cultured neonatal rat heart muscle cells. J. Mol Cell Cardiol. 5(45):45-58
55. Milano CA, Dolber PC, Rockman HA, Bond RA, Venable ME, et al. 1994. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 91(21):10109-13
56. Cotecchia S, Exum S, Caron MG, Lefkowitz RJ. 1990. Regions of the alpha 1-adrenergic receptor involved in coupling to phosphatidylinositol hydrolysis and enhanced sensitivity of biological function. Proc. Natl. Acad. Sci. USA 87(8):2896-900
57. Akhter SA, Milano CA, Shotwell KF, Cho M, Rockman HA, et al. 1997. Transgenic mice with cardiac overexpression of alpha-1B adrenergic receptors. In vivo alpha 1-adrenergic receptor-mediated regulation of beta-adrenergic signaling. J. Biol. Chem. 272(34):1253-59
58. Wagner J, Brodde OE. 1978. On the presence and distribution of alpha-adrenoceptors in the heart of various mammalian species. Naunyn Schmiedebergs Arch. Pharmacol. 302(3):239-54
59. Ruffolo RJ, Hieble JP. 1994. Alpha-adrenoceptors. Pharmacol. Ther. 61(1-2): 1-64
60. Rand MJ, Tung LH, Louis WJ, Story DF. 1986. Cardiac alpha-adrenoceptors: postjunctional and prejunctional. J. Mol. Cell Cardiol. 5(17):17-32
61. Ledent C, Denef JF, Cottecchia S, Lefkowitz R, Dumont J, et al. 1997. Costimulation of adenylyl cyclase and phospholipase C by a mutant alpha 1B-adrenergic receptor transgene promotes malignant transformation of thyroid follicular cells. Endocrinology 138(1):369
62. Langer SZ, Duval N, Massingham R. 1985. Pharmacologic and therapeutic significance of alpha-adrenoceptor subtypes. J. Cardiovasc. Pharmacol. 7(Suppl. 8): S1-8
63. Ruffolo RJ, Nichols AJ, Stadel JM, Hieble JP. 1993. Pharmacologic and therapeutic applications of alpha 2-adrenoceptor subtypes. Annu. Rev. Pharmacol. Toxicol. 33(243):243-79
64. Kaumann AJ, Lemoine H. 1987. Beta 2-adrenoceptor-mediated positive inotropic effect of adrenaline in human ventricular myocardium. Quantitative discrepancies with binding and adenylate cyclase stimulation. Naunyn Schmiedebergs Arch. Pharmacol. 335(4):403-11
65. Hall JA, Petch MC, Brown MJ. 1989. Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart. Circ. Res. 65(3):546-53
66. Brodde OE. 1991. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol. Rev. 43(2):203-42; Erratum: 43(3):350
67. Bertin B, Mansier P, Makeh I, Briand P, Rostene W, et al. 1993. Specific atrial overexpression of G protein coupled human beta 1 adrenoceptors in transgenic mice. Cardiovasc. Res. 27(9):1606-12
68. Mansier P, Medigue C, Charlotte N, Vermeiren C, Coraboeuf E, et al. 1996. Decreased heart rate variability in transgenic mice overexpressing atrial beta 1-adrenoceptors. Am. J. Physiol. 271(4):H1465-72
69. Yatani A, Brown AM. 1989. Rapid beta-adrenergic modulation of cardiac calcium channel currents by a fast G protein pathway. Science 245(4913):71-74
70. Pelzer S, Shuba YM, Asai T, Codina J, Birnbaumer L, et al. 1990. Membrane-delimited stimulation of heart cell calcium current by beta-adrenergic signal-transducing Gs protein. Am. J. Physiol. 259(1):H264-67
71. Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, et al. 1994. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor [see comments]. Science 264(5158):582-86
72. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, et al. 1995. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor [see comments]. Nature 374(6519):272-76
73. Shipley JB, Hess ML. 1995. Inotropic therapy for the failing myocardium [see comments]. Clin. Cardiol. 18(11):615-19
74. Kendall MJ, Rajman I. 1994. A risk-benefit assessment of celiprolol in the treatment of cardiovascular disease. Drug Safety 10(3):220-32
75. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, et al. 1996. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94(11)12817-25
76. Heidenreich PA, Lee TT, Massie BM. 1997. Effect of beta-blockade on mortality in patients with heart failure: a metaanalysis of randomized clinical trials. J. Am. Coll. Cardiol. 30(1):27-34
77. Neubauer GE, Gaudron P, Horn M, Hu K, Tian R, et al. 1994. Beta-blockers in cardiac failure. Eur. Heart J. 15(Suppl. C): 16-24
78. Hayashi Y, Takeuchi M, Takaoka H, Hata K, Mon M, et al. 1996. Alteration in energetics in patients with left ventricular dysfunction after myocardial infarction: increased oxygen cost of contractility. Circulation 93(5):932-39
79. Eichhorn EJ, Bristow MR. 1996. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 94(9):2285-96
80. Green SA, Holt BD, Liggett SB. 1992. Beta 1- and beta 2-adrenergic receptors display subtype-selective coupling to Gs. Mol. Pharmacol. 41(5):889-93
81. Levy FO, Zhu X, Kaumann AJ, Birnbaumer L. 1993. Efficacy of beta 1-adrenergic receptors is lower than that of beta 2-adrenergic receptors. Proc. Natl. Acad. Sci. USA 90(22):10798-802
82. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. 1993. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268(31):23116-21
83. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, et al. 1996. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc. Natl. Acad. Sci. USA 93(19):10483-88
84. Murphree SS, Saffitz JE. 1988. Delineation of the distribution of beta-adrenergic receptor subtypes in canine myocardium. Circ. Res. 63(1):117-25
85. Muntz KH, Zhao M, Miller JC. 1994. Downregulation of myocardial beta-adrenergic receptors. Receptor subtype selectivity. Circ. Res. 74(3):369-75
86. Miller JW, Hu ZW, Okazaki M, Fujinaga M, Hoffman BB. 1996. Expression of alpha 1 adrenergic receptor subtype mRNAs in the rat cardiovascular system with aging. Mech. Ageing Dev. 87(2):75-89
87. Cavalli A, Lattion A, Hummler E, Nenninger M, Pedrazzini T, et al. 1997. Decreased blood pressure response in mice deficient of the alpha 1b-adrenergic receptor. Proc. Nat. Acad. Sci. USA 94(21):11589-95
88. Rokosh DG, Bailey BA, Stewart AF, Karns LR, Long CS, et al. 1994. Distribution of alpha 1C-adrenergic receptor mRNA in adult rat tissues by RNase protection assay and comparison with alpha 1B and alpha 1D. Biochem. Biophys. Res. Commun. 200(3):1177-84
89. del Balzo U, Rosen MR, Malfatto G, Kaplan LM, Steinberg SF. 1990. Specific alpha 1-adrenergic receptor subtypes modulate catecholamine-induced increases and decreases in ventricular automaticity. Circ. Res. 67(6):1535-51
90. Surprenant A, Horstman DA, Akbarali H, Limbird LE. 1992. A point mutation of the alpha 2-adrenoceptor that blocks coupling to potassium but not calcium currents. Science 257(5072):977-80
91. Mizobe T, Maghsoudi K, Sitwala K, Tianzhi G, Ou J, et al. 1996. Antisense technology reveals the alpha 2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat [see comments]. J. Clin. Invest. 98(5):1076-80
92. Lakhlani PP, MacMillan LB, Guo TZ, McCool BA, Lovinger DM, et al. 1997. Substitution of a mutant alpha 2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc. Nat. Acad. Sci. USA 94(18):9950-55
93. Gellman RL, Kallianos JA, McNamara JO. 1987. Alpha-2 receptors mediate an endogenous noradrenergic suppression of kindling development. J. Pharmacol. Exp. Ther. 241(3):891-98
94. Loscher W, Czuczwar SJ. 1987. Comparison of drugs with different selectivity for central alpha 1-and alpha 2-adrenoceptors in animal models of epilepsy. Epilepsy Res. 1(3):165-72
95. Deleted in proof
96. Link RE, Stevens MS, Kulatunga M, Scheinin M, Barsh GS, et al. 1995. Targeted inactivation of the gene encoding the mouse alpha 2c-adrenoceptor homolog. Mol. Pharmacol. 48(1):48-55
97. Sallinen J, Link RE, Haapalinna A, Viitamaa T, Kulatunga M, et al. 1997. Genetic alteration of alpha-2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtypenonselective alpha-2-adrenoceptor agonist. Mol. Pharm. 51(1):36-46
98. Shen YT, Cervoni P, Claus T, Vatner SF. 1996. Differences in beta 3-adrenergic receptor cardiovascular regulation in conscious primates, rats and dogs. J. Pharmacol. Exp. Ther. 278(3): 1435-43
99. Bond RA, Clarke DE. 1988. Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes. Br. J. Pharmacol. 95(3):723-34
100. Rohrer DK, Desai KH, Jasper JR, Stevens ME, Regula DJ, et al. 1996. Targeted disruption of the mouse beta 1-adrenergic receptor gene: developmental and cardiovascular effects. Proc. Natl. Acad. Sci. USA 93(14):7375-80
101. Andre C, Erraji L, Gaston J, Grimber G, Briand P, et al. 1996. Transgenic mice carrying the human beta 2-adrenergic receptor gene with its own promoter overexpress beta 2-adrenergic receptors in liver. Eur. J. Biochem. 241(2):417-24
102. Susulic VS, Frederich RC, Lawitts J, Tozzo E, Kahn BB, et al. 1995. Targeted disruption of the beta 3-adrenergic receptor gene. J. Biol. Chem. 270(49):29483-92